Mao-Bai Liu
Overview
Explore the profile of Mao-Bai Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu L, Huang H, Cai Y, Wang Y, Xu B, Liu M, et al.
Eur J Clin Pharmacol
. 2022 Aug;
78(10):1677-1685.
PMID: 36045212
Purpose: This study aimed to investigate the interactions between posaconazole (POS) and intravenously/orally administered cyclosporine A (CsA) in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Methods: We included 118 allogeneic...
2.
Lin W, Cai Z, Chen T, Liu M, Li N, Zheng B
Front Endocrinol (Lausanne)
. 2021 Sep;
12:684960.
PMID: 34484112
Purpose: Dipeptidylpeptidase-4 (DPP-4) inhibitors, including linagliptin, alogliptin, saxagliptin, sitagliptin, and vildagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM) patients in China. This study assessed the economic...
3.
Cheng Y, Chen M, Zhuang Q, Lin B, Chen Y, Yang L, et al.
Pediatr Blood Cancer
. 2021 Jan;
68(5):e28858.
PMID: 33501733
Background: Delayed excretion of methotrexate can lead to life-threatening toxicity that may result in treatment cessation, irreversible organ damage, and death. Various factors have been demonstrated to influence the pharmacokinetic...
4.
Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations
Cheng Y, Wang C, Li Z, Pan Y, Liu M, Jiao Z
Clin Pharmacokinet
. 2020 Sep;
60(1):53-68.
PMID: 32960439
Background And Objective: External evaluation is an important issue in the population pharmacokinetic analysis of antibiotics. The purpose of this review was to summarize the current approaches and status of...
5.
Cheng Y, Lin B, Guo J, Huang B, Fang L, Que W, et al.
Drug Des Devel Ther
. 2019 Nov;
13:3625-3634.
PMID: 31695330
Purpose: The aim of this study is to assess the bioequivalence of a new generic formulation and the branded formulation of levocetirizine dihydrochloride in healthy Chinese volunteers under fasting and...
6.
Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, et al.
Clin Ther
. 2019 Jan;
41(2):280-290.
PMID: 30639208
Purpose: This study aimed to evaluate the cost-effectiveness of osimertinib with gefitinib or erlotinib as first-line and sequential therapy for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer...
7.
Que W, Qiu H, Cheng Y, Liu M, Wu C
Clin Chim Acta
. 2018 Feb;
480:92-98.
PMID: 29408173
Background: Kidney cancer is one of the most common cancers in the USA causing 14,400 deaths per year. The phosphatase and tensin homolog (PTEN) has been extensively documented as a...
8.
Li N, Zheng B, Cai H, Yang J, Luo X, Weng L, et al.
Clin Drug Investig
. 2017 Oct;
38(1):79-86.
PMID: 29027641
Background And Objective: Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is...
9.
Zhao Z, Xu X, Liu M, Wu J, Lin J, Li B
Am J Infect Control
. 2014 Apr;
42(5):e61-4.
PMID: 24773806
Background: Carbapenem-resistant Enterobacteriaceae (CRE) is widespread in China. To date, no study available has specifically determined the prevalence and risk factors of inpatients with CRE intestinal colonization in this region....